Document is current
Any future updates will be listed below
-
Authors
Yagi, Chiaki
Kuroda, Shinji https://orcid.org/0000-0002-4484-1253
Kakiuchi, Yoshihiko
Hanzawa, Shunya
Kadowaki, Daisuke
Yoshida, Yusuke
Sakamoto, Masaki
Hamada, Yuki
Sugimoto, Ryoma
Ohtani, Tomoko
Kumon, Kento
Hashimoto, Masashi
Kanaya, Nobuhiko
Kikuchi, Satoru
Kagawa, Shunsuke
Tazawa, Hiroshi
Urata, Yasuo
Fujiwara, Toshiyoshi
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP22ck0106569h0003)
- License Information
-
More Information
Article History
Received: 3 July 2025
Accepted: 29 September 2025
First Online: 4 November 2025
Declarations
:
: Yasuo Urata is the President and CEO of Oncolys BioPharma, Inc., the manufacturer of OBP-301, OBP-401, and OBP-502. Hiroshi Tazawa and Toshiyoshi Fujiwara are consultants for Oncolys BioPharma, Inc. The remaining authors declare no competing interests.
